Mydecine Innovations Group Inc. (“Mydecine” or the
“Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a
biotechnology company engineering the next wave of innovative
medications and treatment protocols to directly address mental
health with a particular emphasis on addiction and PTSD, is pleased
to announce that, in connection with: (i) its previously announced
Common Share Subscription Agreement (the “
Opensky
Subscription Agreement”) with OpenSky
Opportunities Fund Ltd. (“
Opensky”) dated 10 March
2023; and (ii) a Common Share Subscription Agreement dated 25
October 2023 (the “
Standalone Subscription
Agreement”, and collectively with the Opensky Subscription
Agreement, the “
Subscription Agreements”) between
the Company and an arms-length investor (the “
Standalone
Investor” and collectively with Opensky, the
“
Investors”), the Company has filed a shelf
prospectus supplement (the “
Prospectus
Supplement”) to the Company’s Final Short Form Base Shelf
Prospectus for the province of Québec and Amended and Restated
Final Short Form Base Shelf Prospectus for each of the provinces of
Canada, dated 28 January 2022 (together, the “
Shelf
Prospectus”).
The Prospectus Supplement provides, among other
things, that the Company is qualifying the distribution of up to
7,360,000 common shares (each a “Share”) in the
capital of the Company to the Investors under the Subscription
Agreements at a price of $0.15 per Share for aggregate gross
proceeds of up to $1,104,000.
The Company also announces today the closing of
Share issuances under the Subscription Agreements (the
“Offerings”). The Offerings resulted in the
issuance of 7,360,000 Shares at a price of $0.15 per Share for
aggregate gross proceeds of $1,104,000. The distribution of such
Shares is qualified by the Prospectus Supplement. The Company will
use the proceeds of the Offering as described in the Prospectus
Supplement.
An application will be made to the Aquis Stock
Exchange ("Aquis") for the 7,360,000 new Shares to be admitted to
trading. Admission is expected to take place, and dealings on Aquis
in the Shares are expected to commence, at 08:00 on or around 3
November 2023.
Following Admission, the Company will have
52,567,458 Ordinary Shares in issue. Since the Company currently
holds no shares in treasury, the total number of voting rights in
the Company will therefore be 52,567,458. These figures may
therefore be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
The Prospectus Supplement and Base Shelf
Prospectus are available on the Company website and on the
Company’s profile on the System for Electronic Document Analysis
and Retrieval (SEDAR+) at www.sedarplus.ca.
About Mydecine
Innovations Group
Inc.
Mydecine Innovations Group is a publicly traded,
pre-revenue biopharmaceutical company that began operations in
North America and Europe in early 2020. Mydecine was founded to
increase physicians' access to serotonin-modulating medicine.
Recent research has demonstrated the therapeutic potential of
psychedelic substances such as psilocybin and MDMA for treating
intractable conditions such as pain, anxiety, depression,
addiction, and PTSD, along with neurodegenerative disorders.
Mydecine believes these compounds can be safer, more effective, and
more accessible for patients and medical professionals through
modern drug chemistry paired with artificial intelligence (AI).
Through its exclusive partnership with Applied Pharmaceutical
Innovation based at the University of Alberta, Mydecine is
developing innovative medications for target indications with high
mortality rates that have lacked innovation for decades and are
controlled by dominant corporations. Mydecine developed several
prodrug families, beginning with a psilocybin-derived smoking
cessation drug undergoing a NIDA-funded trial at Johns Hopkins
University. Mydecine is also developing MYCO-006—short-acting
chemical analogs derived from MDMA for treating various conditions,
including anxiety and pain. Mydecine utilises cutting-edge
artificial intelligence (AI) and pharma research infrastructure at
the University of Alberta to develop and manufacture new
medications to make them affordable and accessible to the general
public upon Health Canada and FDA approval. The Mydecine team is
enthusiastic about its mission and is dedicated to creating a
positive difference in the lives of others.
The Directors of Mydecine take responsibility
for this announcement.
This announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Learn more at: https://www.mydecine.com/ and
follow the company on Twitter, LinkedIn, YouTube, and
Instagram.
For more
information, please
contact:
Media
Contactpr@mydecineinc.com
Investor
Relationsinvestorrelations@mydecineinc.com
On behalf of
the Board of
Directors
Joshua Bartch,
Chief Executive
Officer
contact@mydecineinc.com
AQSE Corporate AdvisorNovum Securities
Limited Tel:
+44 (0)207 399 9400David Coffman/ George Duxberry
For further information about Mydecine, please
visit the Company’s profile on SEDAR at https://sedar.com/ or visit
the Company’s website at https://www.mydecine.com/.
Forward-Looking
Statements
Certain statements in this news release
constitute “forward-looking information” within the meaning of
applicable Canadian securities legislation. Forward-looking
statements and information are provided for the purpose of
providing information about management’s expectations and plans
relating to the future. All of the forward-looking information made
in this news release is qualified by the cautionary statements
below and those made in our other filings with the securities
regulators in Canada. Forward-looking information contained in
forward-looking statements can be identified by the use of words
such as “are expected,” “is forecast,” “is targeted,”
“approximately,” “plans,” “anticipates,” “projects,” “anticipates,”
“continue,” “estimate,” “believe” or variations of such words and
phrases or statements that certain actions, events or results
“may,” “could,” “would,” “might,” or “will” be taken, occur or be
achieved. All statements, other than statements of historical fact,
may be considered to be or include forward-looking information.
This news release contains forward-looking information regarding,
the use of proceeds and the closing of the Offering. Readers are
cautioned that these forward-looking statements are neither
promises nor guarantees, and are subject to risks and uncertainties
that may cause future results to differ materially from those
expected. Although the Company has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such information.
The forward-looking information set forth herein
reflects the Company’s reasonable expectations as at the date of
this news release and is subject to change after such date. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise, other than as required by
law. The forward-looking information contained in this news release
is expressly qualified by this cautionary statement.
This news
release shall
not constitute
an offer to
sell or the
solicitation of
an offer to
buy nor shall
there be any sale
of the
securities in
any State in
which such
offer, solicitation
or sale would
be unlawful. The
securities being offered have not been,
nor will they be, registered under the United States Securities Act
of 1933, as amended, and may not be offered or sold in the United
States absent registration or an applicable exemption from the
registration requirements
of the United
States Securities
Act of 1933,
as amended, and
applicable state
securities laws.
MYDECINE INNOVATIONS GROUP INC.Suite 810–789 West
Pender Street, Vancouver, British Columbia, V6C 1H2 T:
604-687-2038
Mydecine Innovations (AQSE:MYIG)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Mydecine Innovations (AQSE:MYIG)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024